» Articles » PMID: 25745540

Factors Influencing Adherence to Imatinib in Indian Chronic Myeloid Leukemia Patients: a Cross-sectional Study

Overview
Date 2015 Mar 7
PMID 25745540
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Adherence to imatinib(IM) is of utmost importance in patients with chronic myeloid leukemia (CML) to maximise treatment effectiveness. The main objective is to measure adherence to IM by evaluating individual patient characteristics, personal behaviour and, treatment related psychological factors influencing adherence behaviour. Hundred patients receiving IM were analysed for adherence behaviour using 9 item Morisky Medication Adherence Scale (9-MMAS). Various factors were assessed for their impact on adherence behaviour. These factors were age, gender, duration of treatment, frequency and dosing of treatment, use of tobacco and alcohol, educational qualification, employment status, monthly income, side effects, financial assistance in treatment, social support, knowledge about medicine and disease, concomitant drug burden, polypharmacy, physician patient interaction, patient educational sessions and prevalence of depression. Seventy five percent of patients were found to be adherent. On univariate analysis, prevalence of depression (p<0.000001), moderate severe depression (p<0.000001), concomitant drug burden (p=0.036) and monthly income (p=0.015) were found to be significantly influencing adherence. The final multivariate model retained prevalence of depression with OR= 10.367 (95% CI, 3.112-34.538) as independent predictor of adherence to therapy. This study suggests that identification and treatment of depression among CML patients may further enhance adherence to IM therapy.

Citing Articles

Side effects of treatment with tyrosine kinase inhibitors in patients with chronic myeloid leukaemia and the occurrence of depressive symptoms.

Gibek K Contemp Oncol (Pozn). 2024; 27(4):277-283.

PMID: 38405209 PMC: 10883194. DOI: 10.5114/wo.2023.135362.


Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol.

Ramsdale E, Mohamed M, Holmes H, Zubkoff L, Bauer J, Norton S J Geriatr Oncol. 2024; 15(2):101687.

PMID: 38302299 PMC: 10923001. DOI: 10.1016/j.jgo.2023.101687.


Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia.

Adattini J, Adiwidjaja J, Gross A, McLachlan A Pharmacol Res Perspect. 2023; 11(4):e01082.

PMID: 37417254 PMC: 10326685. DOI: 10.1002/prp2.1082.


Examining anxiety and depression in haematology cancer patients in ongoing treatment and under watchful waiting: A systematic review and meta-analysis.

Russell K, Moghaddam N, Tickle A Eur J Cancer Care (Engl). 2022; 31(6):e13678.

PMID: 35977801 PMC: 9787612. DOI: 10.1111/ecc.13678.


miR-506 in patients with chronic myeloid leukemia and its effect on apoptosis of K562 cells.

Chen N, Meng Z, Song J, Kong L, Zhang Y, Guo S Am J Transl Res. 2021; 13(8):9413-9420.

PMID: 34540060 PMC: 8430173.


References
1.
Darkow T, Henk H, Thomas S, Feng W, Baladi J, Goldberg G . Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007; 25(6):481-96. DOI: 10.2165/00019053-200725060-00004. View

2.
Grenard J, Munjas B, Adams J, Suttorp M, Maglione M, McGlynn E . Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med. 2011; 26(10):1175-82. PMC: 3181287. DOI: 10.1007/s11606-011-1704-y. View

3.
Dos Reis S, Quixada A, Nunes S, Cid D, de Souza J, Costa C . Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital. Rev Bras Hematol Hemoter. 2013; 35(3):174-9. PMC: 3728129. DOI: 10.5581/1516-8484.20130053. View

4.
Markkula A, Hietala M, Henningson M, Ingvar C, Rose C, Jernstrom H . Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort. Cancer Prev Res (Phila). 2012; 5(5):735-45. DOI: 10.1158/1940-6207.CAPR-11-0442. View

5.
Ibrahim A, Eliasson L, Apperley J, Milojkovic D, Bua M, Szydlo R . Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011; 117(14):3733-6. PMC: 6143152. DOI: 10.1182/blood-2010-10-309807. View